Proton Pump Inhibitor Prescriptions and Subsequent Use in US Veterans Diagnosed with Gastroesophageal Reflux Disease

被引:23
|
作者
Gawron, Andrew J. [1 ,2 ,3 ]
Pandolfino, John E. [1 ]
Miskevics, Scott [3 ]
LaVela, Sherri L. [2 ,3 ]
机构
[1] Northwestern Univ, Feinberg Sch Med, Div Gastroenterol & Hepatol, Chicago, IL 60613 USA
[2] Northwestern Univ, Feinberg Sch Med, Ctr Healthcare Studies, Chicago, IL 60613 USA
[3] Edward Hines Jr VA Hosp, Dept Vet Affairs, Ctr Management Complex Chron Care, Hines, IL USA
基金
美国医疗保健研究与质量局;
关键词
drug; GERD; prescriptions; Veteran Health Affairs; RISK; ADHERENCE; THERAPY; MEDICATION; MAGNITUDE; FRACTURE; OVERUSE; IMPACT;
D O I
10.1007/s11606-013-2345-0
中图分类号
R19 [保健组织与事业(卫生事业管理)];
学科分类号
摘要
Empiric proton pump inhibitor use is common for gastroesophageal reflux disease (GERD), but initial proton pump inhibitor (PPI) prescription patterns in Veterans are unknown. The study aims were to determine initial PPI prescriptions in Veterans diagnosed with GERD, and to characterize subsequent PPI use over the 2 years following initial prescription. We conducted a retrospective study using Veteran's Administration (VA) administrative data and chart review. Patients diagnosed with GERD and provided an initial PPI prescription at Hines VA Hospital from 2003 to 2007, with 2 year follow-up for each patient (through 2009). Initial PPI prescriptions were categorized as standard total daily dose or high total daily dose, and accuracy was confirmed by manual chart review. Descriptive statistics were calculated and bivariate analyses were used to assess for differences in demographics, prescriptions, and subsequent use by initial PPI dosage category. Of the 1,621 patients included in the study, 378 (23.3 %) had high total daily dose initial PPI prescriptions and 1,243 (76.7 %) patients had standard total daily dose initial prescriptions. The majority of patients (65.8 %) received a 90-day or greater initial prescription. Over the 2 years following the initial PPI prescription, 13.0 % of patients with initial standard daily dose prescriptions had evidence of step-up therapy. Only 7.1 % of patients with initial high daily dose PPI prescriptions had evidence of step-down therapy. A large majority of patients (83.8 %) had at least one refill over 2 years, and the overall medication possession ratio was 0.86. Many Veterans receive high total daily dose PPI prescriptions as initial therapy for a GERD diagnosis, and few patients have evidence for cessation or reduction of therapy. These results provide detailed data on prescribing and use of PPIs to help guide efforts for optimal PPI use in US Veterans.
引用
收藏
页码:930 / 937
页数:8
相关论文
共 50 条
  • [41] Persistent gastroesophageal reflux disease symptoms on standard proton-pump inhibitor therapy
    Sontag, SJ
    GASTROENTEROLOGY CLINICS OF NORTH AMERICA, 2002, 31 (04) : S77 - +
  • [42] Effect of a Preoperative Proton Pump Inhibitor and Gastroesophageal Reflux Disease on Postoperative Nausea and Vomiting
    Kwon, Young Suk
    Choi, Jun Woo
    Lee, Ho Seok
    Kim, Jong Ho
    Kim, Youngmi
    Lee, Jae Jun
    JOURNAL OF CLINICAL MEDICINE, 2020, 9 (03)
  • [43] Response of Regurgitation to Proton Pump Inhibitor Therapy in Clinical Trials of Gastroesophageal Reflux Disease
    Kahrilas, Peter J.
    Howden, Colin W.
    Hughes, Nesta
    AMERICAN JOURNAL OF GASTROENTEROLOGY, 2011, 106 (08): : 1419 - 1425
  • [44] The putative mechanisms for proton pump inhibitor's failure in patients with gastroesophageal reflux disease
    Fass, Ronnie
    ACTA PHARMACOLOGICA SINICA, 2006, 27 : 42 - 42
  • [45] Proton-pump inhibitor therapy for gastroesophageal reflux disease - Does it treat the asthma?
    Jain, S
    CHEST, 2005, 127 (04) : 1097 - 1098
  • [46] Predictors for proton pump inhibitor failure in non-erosive gastroesophageal reflux disease
    Shi, Yinan
    Xiao, Yinglian
    Chen, Minhu
    JOURNAL OF GASTROENTEROLOGY AND HEPATOLOGY, 2013, 28 : 60 - 60
  • [47] From Gastroesophageal Reflux to Gastric Pseudomelanosis: A Rare Complication of Chronic Proton Pump Inhibitor Use
    Sierra, Leandro
    Yibirin, Marcel
    Alsaqa, Marwan
    Parraga, Carla Barberan
    Calderon, Joaquin A.
    Razzak, Iyiad Alabdul
    Shalabi, Najib
    Suarez, Zoilo K.
    AMERICAN JOURNAL OF GASTROENTEROLOGY, 2024, 119 (10S): : S2393 - S2393
  • [48] Gastroesophageal reflux disease, proton-pump inhibitor use and Barrett's esophagus in esophageal adenocarcinoma: Trends revisited
    Lada, Michal J.
    Nieman, Dylan R.
    Han, Michelle
    Timratana, Poochong
    Alsalahi, Omran
    Peyre, Christian G.
    Jones, Carolyn E.
    Watson, Thomas J.
    Peters, Jeffrey H.
    SURGERY, 2013, 154 (04) : 856 - 864
  • [49] Relationship between long-term use of proton pump inhibitor (PPI) and hypomagnesemia in patients with gastroesophageal reflux disease
    Arj, Abbas
    Takizadeh, Zeinab Ghale
    Gilassi, Hamidreza
    Razavizadeh, Mohsen
    CASPIAN JOURNAL OF INTERNAL MEDICINE, 2022, 13 (01) : 107 - 112
  • [50] Effect of potassium competitive acid blocker compared to proton pump inhibitor in gastroesophageal reflux disease
    Wepee, Roderick, Jr.
    Te, Marilyn
    JOURNAL OF GASTROENTEROLOGY AND HEPATOLOGY, 2021, 36 : 278 - 278